Journal article
Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges
Drugs & aging, Vol.26(11), pp.917-931
2009
DOI: 10.2165/11318270-000000000-00000
PMID: 19848438
Abstract
Although HMG-CoA reductase inhibitors (statins) have been shown to reduce the risk of cardiovascular events in patients aged 65-80 years who have clinical cardiovascular disease, fewer data are available for elderly patients without cardiovascular disease. Treatment guidelines recommend a low-density lipoprotein cholesterol goal of <100 mg/dL for those with cardiovascular disease or diabetes mellitus but vary in their recommendations for primary prevention. Moderate-dose statins have been shown to be effective and safe in properly selected elderly patients up to the age of 80 years. High-dose statins have also been shown to be effective and reasonably safe in patients without significant co-morbidities up to the age of 75 years. With advancing age, the potential for benefit from cholesterol-lowering treatment needs to be weighed against the increasing risk of muscle and hepatic toxicity, as well as competing causes of morbidity and mortality.
Details
- Title: Subtitle
- Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges
- Creators
- Jennifer G Robinson - Lipid Research Clinic, Departments of Epidemiology & Medicine, University of Iowa, Iowa City, Iowa 52242, USA. jennifer-g-robinson@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Drugs & aging, Vol.26(11), pp.917-931
- Publisher
- New Zealand
- DOI
- 10.2165/11318270-000000000-00000
- PMID
- 19848438
- ISSN
- 1170-229X
- eISSN
- 1179-1969
- Grant note
- 5 U18 HSO16094 / PHS HHS
- Language
- English
- Date published
- 2009
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995137902771
Metrics
14 Record Views